| Date | Title | Description |
| 08.10.2024 | Commencement of trading on OTCQB in the United States | LONDON and NEW YORK, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (LSE: RENX) (OTCQB: RNLXY), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved ... |
| 11.07.2024 | Renalytix and Steno Diabetes Center Announce Precision Medicine Collaboration Marking First Expansion for KidneyIntelX Platform Beyond US | LONDON and NEW YORK, July 11, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved ... |
| 27.06.2024 | Renalytix Submits Hearing Request to Nasdaq Hearings Panel in Regard to Staff Delisting Determination | LONDON and NEW YORK, June 27, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (Nasdaq: RNLX) (LSE: RENX) announces that it has formally submitted a hearing request to the Nasdaq Hearings Panel (the “Panel”), which request has now stayed the suspensi... |
| 08.04.2024 | Renalytix Secures $4 Million in Financing | Renalytix plc (NASDAQ: RNLX) (LSE: RENX) has locked in a registered direct offering of ordinary shares with DB Capital Partners Healthcare, L.P. The offering, priced at $0.75 per NASDAQ ADS ($0.375 per common stock share), is expected to br... |
| 08.04.2024 | Renalytix Announces Financing with Expected Size of up to $4 Million | - |
| 08.04.2024 | Renalytix Announces Financing with Expected Size of up to $4 Million | LONDON and SALT LAKE CITY, April 08, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces a registered direct offering of ordinary shares at a purchase price equivalent to $0.75 per NASDAQ ADS ($0.375 per common stock... |
| 09.02.2024 | Renalytix to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference | LONDON and SALT LAKE CITY, Feb. 09, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) (the “Company”) today announced that the Company will be participating in the upcoming BTIG MedTech, Digital Health, Life Science & Di... |
| 03.07.2023 | Renalytix Appoints Financial Executive Catherine Coste to its Board of Directors | /EIN News/ -- LONDON and SALT LAKE CITY, July 03, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), the first company to commercialize an FDA approved artificial intelligence (AI) enabled prognostic blood test for individua... |
| 09.06.2023 | Renalytix Reports Financial Results for Third Quarter of Fiscal Year 2023 | /EIN News/ -- LONDON and SALT LAKE CITY, June 09, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney diseas... |
| 09.02.2023 | Renalytix to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference | /EIN News/ -- LONDON and SALT LAKE CITY, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the Company will be participating in the upcoming BTIG MedTech, Digital Health, Life Science & Diagnosti... |
| 26.01.2023 | Renalytix and Partners Awarded $10 Million Horizon Europe Grant to Advance Personalized Medicine in Treating CKD Throughout Europe and the United States | - |
| 22.11.2022 | Renalytix to Report Financial Results for First Quarter Fiscal Year 2023 on November 30 | LONDON and SALT LAKE CITY, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Renalytix plc RNLX RENX announces that it will report its first quarter fiscal year 2023 financial results on Wednesday, November 30, 2022, before market open. The Company will ho... |
| 03.11.2022 | Renalytix to Present at Stifel Healthcare Conference | /EIN News/ -- NEW YORK and SALT LAKE CITY, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the Company will participate in the Stifel Healthcare Conference to be held November 15-16, 2022 at the Lo... |
| 31.10.2022 | Renalytix Reports Full Year Fiscal 2022 Results | LONDON and SALT LAKE CITY, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX), (LSE: RENX) an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive imp... |
| 24.10.2022 | Renalytix to Report Financial Results for Fourth Quarter and Full Year Fiscal 2022 on October 31 | NEW YORK and SALT LAKE CITY, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the Company will report its fourth quarter and full year fiscal 2022 financial results on Monday, October 31, 2022, befo... |
| 24.10.2022 | Renalytix to Report Financial Results for Fourth Quarter and Full Year Fiscal 2022 on October 31 | /EIN News/ -- NEW YORK and SALT LAKE CITY, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the Company will report its fourth quarter and full year fiscal 2022 financial results on Monday, October ... |
| 08.09.2022 | Renalytix to Present at H.C. Wainwright 24th Annual Global Investment Conference | NEW YORK and SALT LAKE CITY, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the company will participate in a fireside chat at the H.C. Wainwright 24th Annual Global Investment Conference to be h... |
| 23.06.2022 | Renalytix to Report Financial Results for Third Quarter Fiscal 2022 on June 30 | NEW YORK and SALT LAKE CITY, June 23, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the Company will report its third quarter fiscal 2022 financial results on Thursday, June 30, 2022, before market open. ... |
| 08.04.2022 | Renalytix plc successful completion of $30.0 million financing package | NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, THE REPUBLIC OF SOUTH AFRICA, NEW ZEALAND OR IN OR INTO ANY OTHER JURISDICTION IN WHICH OFFERS... |
| 31.03.2022 | Renalytix announces a $30.0 million financing package | NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, THE REPUBLIC OF SOUTH AFRICA, NEW ZEALAND OR IN OR INTO ANY OTHER JURISDICTION IN WHICH OFFERS... |
| 31.03.2022 | Renalytix Reports Financial Results for Second Quarter of Fiscal Year 2022 | LONDON and SALT LAKE CITY, March 31, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive im... |
| 25.03.2022 | Renalytix to Report Second Quarter and First Half Fiscal Year 2022 Financial Results on March 31 | NEW YORK and SALT LAKE CITY, March 25, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the Company will release its second quarter and first half fiscal year 2022 financial results on Thursday, March 31, 20... |
| 05.01.2022 | Renalytix to Present at 40th Annual J.P. Morgan Virtual Healthcare Conference | NEW YORK and SALT LAKE CITY, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (LSE: RENX) (NASDAQ: RNLX) (“Renalytix” or the “Company”) today announced the Company will be presenting at the upcoming 40th Annual J.P. Morgan Virtual Healthcare... |
| 07.12.2021 | Renalytix Reports Financial Results for First Quarter of Fiscal Year 2022 | NEW YORK and SALT LAKE CITY, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive i... |
| 02.12.2021 | Renalytix to Report First Quarter Fiscal Year 2022 Financial Results on December 7 | NEW YORK and SALT LAKE CITY, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the Company will release first quarter fiscal year 2022 financial results on Tuesday, December 7, 2021, before market op... |
| 09.11.2021 | St. Joseph’s Health and Renalytix Partner to Advance Value-Based Kidney Health in New York | NEW YORK, Nov. 09, 2021 (GLOBE NEWSWIRE) -- St. Joseph's Health and Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced a partnership to implement an advanced clinical care model designed to improve kidney health in patients with type ... |
| 21.10.2021 | Renalytix Reports Full Year Fiscal 2021 Results | LONDON and SALT LAKE CITY, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX), (LSE: RENX) an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive imp... |
| 08.10.2021 | Renalytix to Report Fourth Quarter and Full Year Fiscal 2021 Financial Results on October 21 | LONDON and SALT LAKE CITY, Oct. 08, 2021 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the Company will release fourth quarter and full year fiscal 2021 financial results on Thursday, October 21, 2021, before ... |
| 07.10.2021 | Renalytix Launching KidneyIntelX in Veterans Health Administration Hospitals | NEW YORK and SALT LAKE CITY, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the expansion of its commercial strategy to address early-stage kidney disease in the Veterans Health Administration pat... |
| 15.06.2021 | Renalytix Reports Financial Results for Third Quarter of Fiscal Year 2021 | NEW YORK, June 15, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX) (“Renalytix” or the “Company”) today reported financial results for the quarter and nine months ended March 31, 2021.
Recent Highlights Partnership anno... |
| 15.06.2021 | RENALYTIX AI PLC
Renalytix Reports Financial Results for Third Quarter of Fiscal Year 2021 | NEW YORK, June 15, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX) (“Renalytix” or the “Company”) today reported financial results for the quarter and nine months ended March 31, 2021.
Recent Highlights Partnership anno... |
